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Abstract
During infection significant alterations in lipid metabolism and lipoprotein
composition occur. Triglyceride and VLDL cholesterol levels increase, while
reduced HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels are
observed. More importantly, endotoxemia modulates HDL composition and
size: phospholipids are reduced as well as apolipoprotein (apo) A-I, while
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serum amyloid A (SAA) and secretory phospholipase A2 (sPLA2) dramatically
increase, and, although the total HDL particle number does not change, a
significant decrease in the number of small- and medium-size particles is
observed. Low HDL-C levels inversely correlate with the severity of septic
disease and associate with an exaggerated systemic inflammatory response.
HDL, as well as other plasma lipoproteins, can bind and neutralize Gram-
negative bacterial lipopolysaccharide (LPS) and Gram-positive bacterial
lipoteichoic acid (LTA), thus favoring the clearance of these products. HDLs
are emerging also as a relevant player during parasitic infections, and a specific
component of HDL, namely, apoL-1, confers innate immunity against trypano-
some by favoring lysosomal swelling which kills the parasite. During virus
infections, proteins associated with the modulation of cholesterol bioavailability
in the lipid rafts such as ABCA1 and SR-BI have been shown to favor virus entry
into the cells. Pharmacological studies support the benefit of recombinant HDL
or apoA-I mimetics during bacterial infection, while apoL-1–nanobody
complexes were tested for trypanosome infection. Finally, SR-BI antagonism
represents a novel and forefront approach interfering with hepatitis C virus entry
which is currently tested in clinical studies. From the coming years, we have to
expect new and compelling observations further linking HDL to innate immu-
nity and infections.
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Abbreviations
ABCA-1 ATP-binding cassette transporter 1
ApoA-I Apolipoprotein A-I
ApoE Apolipoprotein E
ApoL-1 Apolipoprotein L-1
ApoM Apolipoprotein M
IL-1β Interleukin-1β
IL-6 Interleukin-6
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HDL-C HDL cholesterol
LBP LPS-binding protein
LCAT Lecithin-cholesterol acyltransferase
LDL-C LDL cholesterol
LPS Gram-negative bacterial lipopolysaccharide
LTA Gram-positive bacterial lipoteichoic acid
PAF-AH Platelet-activating factor acetylhydrolase
484 A. Pirillo et al.
PON1 Serum paraoxonase
PTX3 Pentraxin 3
rHDL Reconstituted HDL
SAA Serum amyloid A
S1P Sphingosine-1-phosphate
sPLA2 Secretory phospholipase A2
SR-BI Scavenger receptor class B member 1
TG Triglycerides
TLF-1 Trypanosome lytic factor-1
TLRs Toll-like receptors
TNF-α Tumor necrosis factor-α
1 Introduction
HDLs are heterogeneous particles generated by the continuous remodeling by
lipolytic enzymes and lipid transporters and by lipid and apolipoprotein exchange
with other circulating lipoproteins and tissues (Kontush and Chapman 2006).
Mature HDL particles have a hydrophobic core containing cholesteryl esters and
triglycerides, while proteins are embedded in a lipid monolayer composed mainly
of phospholipids and free cholesterol. HDLs contain two main proteins, apolipo-
protein A-I (apoA-I) and apoA-II, but several other minor apoproteins as well as
enzymes such as lecithin-cholesterol acyltransferase (LCAT), serum paraoxonase
(PON1), and platelet-activating factor acetylhydrolase (PAF-AH) are associated
with HDL particles (Navab et al. 2004). HDLs possess several biological functions
(Pirillo et al. 2013), but the role of HDL in innate immunity has emerged in the
1970s with the first observation associating HDL cholesterol (HDL-C) plasma
levels to protection against sepsis. In the coming years, it has emerged that the
ability of HDL to modulate cholesterol bioavailability in the lipid rafts, membrane
microdomains enriched in glycosphingolipids and cholesterol, is evolutionary
conserved and affects the properties of cells involved in the innate and adaptive
immune response, tuning inflammatory response and antigen presentation functions
in macrophages as well as activation of B and T cells. In the context of infections,
HDL and their components have been linked with protection toward Gram-negative
and Gram-positive bacteria and parasites, while the role during virus infection is
debated (Fig. 1). Furthermore, HDLs influence humoral innate immunity by tuning
the activation of the complement system and the expression of pentraxin 3 (PTX3).
HDLs are critical not only during sepsis but also in other bacterial, parasitic, and
viral infection. The aim of this chapter is to discuss the relevant findings on the link
between HDL and immune response, shedding a new light on the role of these
lipoproteins during sepsis and infectious disease.
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2 HDL and Bacterial Infections
Increasing observations suggest that persistent low-grade inflammation is
associated with the pathogenesis of severe chronic diseases such as atherosclerosis,
diabetes, and other aging-related neurological diseases. Low levels of circulating
Gram-negative bacterial endotoxin lipopolysaccharide (LPS) appear to sustain a
non-resolving low-grade inflammation. As a consequence, low-grade
endotoxinemia may skew host immune environment into a mild non-resolving
pro-inflammatory state, which eventually leads to the pathogenesis and progression
of inflammatory diseases.
During infection, significant changes in the lipid metabolism are observed. At
first, plasma levels of lipid and lipoproteins may change: triglyceride (TG) and
VLDL cholesterol levels increase due to several mechanisms, including reduction
of TG hydrolysis, LPS- and pro-inflammatory cytokines-induced de novo free fatty
acid production, and TG synthesis in the liver and reduction of lipoprotein lipase
activity thus resulting in reduced VLDL clearance and increased TG levels (Wendel
et al. 2007). In addition, the increase in free fatty acids induces insulin resistance,
thus contributing to increased glucose levels during systemic inflammation. On the
other hand, HDL-C and LDL-C levels decrease during sepsis, and a low plasma
Bacteria
Parasites
Virus
HDL
TYPE OF INFECTION HDL-MEDIATED EFFECT
•Favor LPS/LTA binding and neutralizaon.
•Favor LPS/LTA clearance
• Inhibit LPS (LTA)-induced cytokine release
• Inhibit of LPS (LTA)-induced cell acvaon
• Induce an early inﬂammatory response
•Support ApoL1, Apo-AI and HRP interacon 
to form the trypanosoma lyc factor-1  (TLF-
1). complex. ApoL1  then traﬃcs to the 
trypanosomal lysosome, where causes 
swelling which kills the trypanosome.
•Dampen (ApoA-1 mimec pepdes) the 
ABCA-1 impairment induced by the HIV-1 
Nef protein.
• Inhibit cell fusion, both in HIV-1-infected T 
cells and in recombinant vaccinia-virus-
infected CD4+ HeLa cells.
•Compete with Hepas C virus on SRBI 
interacon to dampen virus entry?
Fig. 1 HDL and infections
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HDL-C level (associated with a low plasma apoA-I level) is a poor prognostic
factor for severe sepsis, as it is associated with increased mortality and adverse
clinical outcomes (Chien et al. 2005); more importantly, significant alterations in
lipoprotein composition are observed, and increased levels of acute-phase proteins,
including serum amyloid A (SAA) and secretory phospholipase A2 (sPLA2), may
contribute to decreased HDL-C levels, by replacing some structural and functional
HDL components (Fig. 2).
Endotoxinemia also modulates HDL composition and size: phospholipids are
reduced while SAA dramatically increases and apoA-I decreases, and, although the
total HDL particle number does not change, a significant decrease in the numbers of
small- and medium-size particles is observed (de la Llera et al. 2012). The apoA-I
content is reduced due to the rapid association of SAA, which displaces apoA-I and
becomes the main protein of acute-phase HDL (Coetzee et al. 1986; Khovidhunkit
et al. 2004); the content of other proteins associated with HDL (PON1, PAF-AH) is
altered, resulting in reduced antioxidant properties of HDL (Feingold et al. 1998)
and increased content of pro-atherogenic lipids (Cao et al. 1998; Memon
et al. 1999). Also the lipid composition of HDL is altered during the acute-phase
response (Khovidhunkit et al. 2004). Endotoxemia induces the increase of some
enzymes involved in HDL remodeling, including endothelial lipase (Badellino
et al. 2008) and secretory phospholipase A2 (de la Llera et al. 2012), and the
decrease of other, such as CETP and LCAT (de la Llera et al. 2012; Wendel
et al. 2007). Altogether these changes result in the loss of functional properties of
HDL (Banka et al. 1995; de la Llera et al. 2012; McGillicuddy et al. 2009).
Infecon/Sepsis
Acute phase-HDL
An-inﬂammatoryacvity
Mature HDL
HDL
PAF-AH AP-HDL
Fig. 2 Acute-phase HDL
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2.1 Interaction of HDL with LPS and Gram-Negative Bacteria
Sepsis is a major cause of death in hospitalized patients. Mortality is mainly due to
the cytotoxic actions of lipid components of the bacterial outer membrane
Lipopolysaccharide (LPS) is the toxic component of endotoxin in the outer mem-
brane of Gram-negative bacteria. Lipoteichoic acid (LTA) is a heat-stable compo-
nent of the cell membrane and wall of most Gram-positive bacteria that shares
structural similarities with LPS and induces cytokine cascades alike LPS
(Grunfeld et al. 1999).
LPS, the major pathogenic factor in Gram-negative sepsis, is an essential
component of the bacterial cell wall, and it is not toxic when incorporated into
the membrane; after release in the blood following bacterial cell reproduction, lysis,
or death, lipid A, the most essential part of LPS, induces an inflammatory response
(Van Amersfoort et al. 2003). This is mediated by pro-inflammatory cytokines
released primarily from monocytes/macrophages and neutrophils, such as tumor
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) (Levine
et al. 1993). LPS is recognized mainly by toll-like receptor 4 (TLR4) in cooperation
with other proteins including MD-2, CD14, and LPS-binding protein (LBP) (Jerala
2007). LBP catalyzes the transfer of LPS to CD14, thus enhancing LPS-induced
cell activation (Van Amersfoort et al. 2003). To prevent exaggerated responses to
LPS, the host has developed several control mechanisms that include inhibitory
LPS-binding proteins and plasma lipoproteins (Van Amersfoort et al. 2003).
In patients with severe sepsis, HDL-C decreases rapidly, and SAA is the major
protein present in HDL (45 %) at the start of sepsis and is slowly replaced by apoA-I
during recovery (van Leeuwen et al. 2003). Low HDL-C levels inversely correlate
with the severity of septic disease and associate with an exaggerated systemic
inflammatory response (Wendel et al. 2007), although it is difficult to establish
whether changes in plasma lipoproteins simply reflect the severity of disease or they
can directly modify the host response to inflammation. Also in healthy subjects low
HDL levels are associated with increased inflammatory response on endotoxin
challenge compared to subjects with normal or high HDL levels (Birjmohun
et al. 2007), without differences in the HDL proteome (Levels et al. 2011). These
observations indicate a positive role of HDL in the protection against sepsis.
Several mechanisms are involved in HDL-mediated protection. HDL, as well as
other plasma lipoproteins (LDL, TG-rich lipoproteins), can bind and neutralize
Gram-negative bacterial LPS as well as Gram-positive bacterial lipoteichoic acid
(LTA) (Grunfeld et al. 1999; Murch et al. 2007). ApoA-I knockout mice, which
lack HDL, exhibit decreased LPS neutralization in the serum compared with serum
from control mice (Guo et al. 2013); overexpression of apoA-I moderately
improves survival compared to controls, suggesting that HDL elevation may
protect against septic death. In endotoxemic rats, in which LPS has been infused
after HDL administration, HDLs attenuate LPS-induced organ damage
accompanied by lower TNF-α and nitric oxide production (Lee et al. 2007). In
addition to its role in LPS neutralization, HDLs exert its protection against
sepsis also by promoting LPS clearance; in fact, almost all LPS exists in the
488 A. Pirillo et al.
complex LPS–HDL in the blood (Ulevitch et al. 1979, 1981), the HDL receptor
SR-BI binds and mediates LPS uptake, and HDLs promote SR-BI-mediated LPS
uptake (Vishnyakova et al. 2003).
Administration of reconstituted HDL (rHDL) efficiently inhibits the
LPS-induced cytokine release from the whole-blood system in vitro (Parker
et al. 1995); however, the first study that demonstrated the LPS-neutralizing ability
of rHDL in humans was performed by intravenous infusion of rHDL before
induction of endotoxemia in healthy volunteers (Pajkrt et al. 1996). rHDL signifi-
cantly reduced endotoxemia-induced inflammatory response, as it reduced clinical
symptoms, reduced inflammatory cytokine (TNF-α, IL-6, IL-8) production, and
attenuated LPS-induced leukocyte activation, in part due to the downregulation of
the main LPS receptor monocyte-bound CD14 (Pajkrt et al. 1996). In
LPS-challenged macrophages, HDLs selectively inhibit the activation of type I
IFN response genes (Suzuki et al. 2010), which play a critical role in the antiviral
response of cells, although emerging evidence also implicates this response in host
defense during bacterial infection. This inhibitory effect of HDL does not require
LPS binding to lipoproteins (Suzuki et al. 2010). HDLs (and apoA-I) attenuate also
LPS-induced neutrophil activation (Murphy et al. 2011). More recently Di Nardo
et al. (2014) have shown that HDLs promote the expression of ATF3 in
macrophages, a transcriptional regulator which inhibits TLR2 expression. Of note
the protective effects of HDL against TLR-induced inflammation were shown to be
fully dependent on ATF3 in vitro and in vivo.
Another mechanism by which HDLs exert a protection against sepsis is by
inducing an early inflammatory response to Gram-negative bacteria, thus helping
to maintain a sensitive host response to LPS; HDLs exert this effect by suppressing
the inhibitory activity of LBP (Thompson and Kitchens 2006). In contrast to native
HDL, recombinant HDL did not increase cell response at early time points and are
strongly inhibitory of cell response; this different effect is due to the composition of
rHDL, which contain only apoA-I and PC and are optimized for LPS binding and
neutralization (Thompson and Kitchens 2006).
Indeed apoA-I is a major HDL component that plays a central role in the anti-
inflammatory functions of this lipoprotein class and exhibits protective effects
against sepsis. ApoA-I in fact can directly inactivate bacterial endotoxin by
protein–protein interaction (Emancipator et al. 1992), being the C-terminal half
of apoA-I the main domain responsible for LPS neutralization (Henning
et al. 2011), but also inhibits LPS-induced cytokine release from human monocytes
(Flegel et al. 1993); in addition, apoA-I reduces TNF-α levels during LPS challenge
in rats and increases the survival rates (Humphries et al. 2006), suggesting that
apoA-I might inhibit LPS binding to macrophages thus inhibiting the production of
inflammatory cytokines that are related to sepsis. In mice, the overexpression of
apoA-I (that results in an increased serum level of both apoA-I and HDL) attenuates
LPS-induced acute injury in lung and kidney (Li et al. 2008); LPS-induced pro-
inflammatory cytokines decrease, as well as CD14 expression in liver and lung,
resulting in a protective effect against systemic inflammation and multiple organ
damage (Li et al. 2008). Similar to what reported in mice, subjects with low plasma
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HDL levels (hypoalphalipoproteinemia) present an increased prevalence of classi-
cal CD14++/CD16 but not of intermediate CD14++/CD16+ monocytes, further
linking HDL- to LPS-mediated responses (Sala et al. 2013). Septic HDLs are
almost depleted of apoC-I (Barlage et al. 2001). ApoC-I contains a consensus
LPS-binding motif and is able to enhance the biological response to LPS thus
reducing mortality in mice with Gram-negative-induced sepsis (Berbee
et al. 2006). In fact, apoC-I binds to LPS and prevents its clearance by the liver
and spleen, resulting in the stimulation of the LPS-induced pro-inflammatory
response and protection against septic death (Berbee et al. 2006). These findings
suggest that when LPS is released into the plasma following bacteria proliferation
in the blood, apoC-I binds to LPS and presents it to responsive cells such as
macrophages, leading to a rapid and enhanced production of pro-inflammatory
cytokines, which are essential for effective eradication of the bacterial infection.
2.2 Interaction of HDL with LTA and Gram-Positive Bacteria
The effects of HDL on components of the bacterial outer membrane are not
restricted to Gram-negative bacteria but also involve cell wall components of
Gram-positive bacteria such as LTA which is able to induce an inflammatory
response similar to that induced by LPS. Indeed it induces a massive production
of mediators of inflammation that may result in systemic inflammatory response
syndrome, septic shock, and multiorgan damage (Bhakdi et al. 1991; De Kimpe
et al. 1995). LTA may also trigger disturbances of lipid metabolism, interfering
with both lipoprotein production and lipoprotein clearance (Grunfeld et al. 1999).
All lipoproteins can bind LTA, but the majority of LTA is found in the HDL
fraction (Levels et al. 2003), suggesting that HDLs have the highest affinity. In
contrast to LPS, HDLs (as well as other lipoproteins) alone do not inhibit the
cytokine production induced by LTA, but require the presence of lipoprotein-
depleted plasma (Grunfeld et al. 1999), suggesting that lipoproteins contain
cofactors in sufficient amounts to facilitate LPS binding to lipoproteins but not
LTA binding. LBP is a plasma component (normally bound to HDL, but it can be
found in lipoprotein-depleted plasma following ultracentrifugation) which
enhances the activation of macrophages by LPS in the absence of lipoproteins
and facilitates LPS binding to lipoproteins; LBP can also bind LTA (Tobias
et al. 1989) and allows HDL to efficiently inactivate LTA (Grunfeld et al. 1999).
The inhibition of LBP with neutralizing antibodies significantly decreases (53 %)
the ability of lipoprotein-depleted plasma to facilitate LTA inactivation, but also
suggests the presence of other plasma factors playing a role in HDL inactivation of
LTA (Grunfeld et al. 1999).
ApoA-I has been shown to bind directly LTA in vitro and to attenuate
LTA-induced NF-kB activation (Jiao and Wu 2008); apoA-I dose-dependently
inhibits L-929 cell death induced by LTA-activated macrophages, and
lipoprotein-depleted plasma strengthened this effect of apoA-I (Jiao and Wu
2008). In mice, apoA-I attenuates LTA-induced acute lung injury and significantly
inhibits LTA-induced pro-inflammatory cytokine production (Jiao and Wu 2008).
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These findings suggest that apoA-I can inhibit LTA activation by multiple
mechanisms, by direct binding to LTA, and by interfering with LTA-mediated
inflammatory response.
2.3 HDL and Mycobacteria
HDLs were reported to be protective also toward intracellular bacteria such as
mycobacteria (Cruz et al. 2008). Intracellular pathogens survive by evading the host
immune system and accessing host metabolic pathways to obtain nutrients for their
growth. Mycobacterium leprae, the causative agent of leprosy, is thought to be the
mycobacterium most dependent on host metabolic pathways, including host-
derived lipids. Although fatty acids and phospholipids accumulate in the lesions
of individuals with the lepromatous (also known as disseminated) form of human
leprosy (L-lep), the origin and significance of these lipids remains unclear. Host-
derived oxidized phospholipids were detected in macrophages within L-lep lesions,
and one specific oxidized phospholipid, 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-
sn-glycero-3phosphorylcholine (PEIPC), accumulates in macrophages infected
with live mycobacteria (Cruz et al. 2008). Mycobacterial infection and host-derived
oxidized phospholipids both inhibited innate immune responses, and this inhibition
was reversed by the addition of normal HDL, a scavenger of oxidized
phospholipids, but not by HDL from patients with L-lep (Cruz et al. 2008). The
accumulation of host-derived oxidized phospholipids in L-lep lesions is strikingly
similar to observations in atherosclerosis, which suggests that the link between host
lipid metabolism and innate immunity could contribute to the pathogenesis of both
microbial infection and metabolic disease.
2.4 General Innate Host Defense Mechanisms Exerted by HDL
After Bacterial Infection
In addition to limiting LPS or LTA responses during infection, HDLs exert addi-
tional functions during the innate immune response. In normal plasma, about 5 % of
HDL particles contain apolipoprotein M (apoM) which binds sphingosine-1-phos-
phate (S1P), an important bioactive lipid mediator known to be associated with
HDL (Christoffersen et al. 2011). The inhibition of apoM production results in the
decrease of HDL-C levels and changes in HDL size, subclass profile, and functions
(Wolfrum et al. 2005); apoM is a negative acute-phase protein that decreases during
infection and inflammation (Feingold et al. 2008); in patients with severe sepsis and
systemic inflammatory response syndrome (SIRS), a leading cause of mortality in
non-coronary intensive care units, apoM plasma levels decrease dramatically
suggesting a reduction of the vasculoprotective effects of apoM and its ligand
S1P, with a strong correlation between apoM decrease and the severity of disease
(Kumaraswamy et al. 2012). It is still unclear whether apoM and S1P levels may
have prognostic value and whether changes in apoM levels contribute to the
pathogenesis of SIRS and septic shock.
HDL in Infectious Diseases and Sepsis 491
Another key player during the immune response regulated by HDL is the long
pentraxin 3 (PTX3). This protein belongs, together with the C-reactive protein
(CRP) and other acute-phase proteins, to the pentraxin superfamily: soluble, multi-
functional, pattern recognition proteins. Pentraxins share a common C-terminal
pentraxin domain, which in the case of PTX3 is coupled to an unrelated long
N-terminal domain (Bonacina et al. 2013). PTX3, which is the prototypic long
pentraxin, was identified in the early 1990s, as a molecule rapidly induced by IL-1
in endothelial cells (ECs) or by TNF-α in both ECs and fibroblasts (Breviario
et al. 1992; Lee et al. 1993). The protein presents a high degree of conservation
from mouse to human (82 % identical and 92 % conserved amino acids) and is
induced in a variety of somatic and innate immunity cells by primary inflammatory
stimuli (Garlanda et al. 2005). PTX3 is a key player of the humoral arm of the
innate immunity, and its physiological functions are associated with the recognition
and binding to different ligands, including microbial moieties, complement
components, and P-selectin. This protein plays also a key role in cardiovascular
diseases including atherosclerosis (Norata et al. 2009, 2010). Similarly to short
pentraxins, PTX3 recognizes the highly conserved pathogen-associated molecular
patterns (PAMPs) expressed by microorganisms (Iwasaki and Medzhitov 2010) and
binds a number of bacteria, fungi, and viruses. A specific binding has been observed
to conidia of Aspergillus fumigatus (Garlanda et al. 2002), Paracoccidioides
brasiliensis, and zymosan (Diniz et al. 2004), to selected Gram-positive and
Gram-negative bacteria (Bozza et al. 2006; Garlanda et al. 2002; Jeannin
et al. 2005), and finally to some viral strains, including human and murine cyto-
megalovirus and influenza virus type A (IVA) (Bozza et al. 2006; Reading
et al. 2008). Both short pentraxin and PTX3 bind apoptotic cells and facilitate
their clearance (Doni et al. 2012; Jaillon et al. 2009). Surface bound CRP activates
the classical pathway of complement through interaction with C1q, thus leading to
cell elimination (Nauta et al. 2003). Cell-bound PTX3 might favor the clearance of
apoptotic cells (Jaillon et al. 2009; Poon et al. 2010) by enhancing the deposition of
both C1q and C3 on cell surfaces (Nauta et al. 2003). On the contrary, when in the
fluid phase, PTX3 interacts with C1q and dampens the deposition on apoptotic cells
and the resulting phagocytosis by dendritic cells and phagocytes (Baruah
et al. 2006; Gershov et al. 2000; Rovere et al. 2000; van Rossum et al. 2004). In
addition to PTX3, C1q recognizes and binds to ficolin-2 and mannose-binding
lectin (MBL), thus modulating the classical and the lectin pathways of complement
activation (Bottazzi et al. 1997). The best described and characterized ligand of
PTX3 is the first component of the classical complement system C1q (Bottazzi
et al. 1997; Nauta et al. 2003); PTX3 interacts with the globular head of the protein
(Roumenina et al. 2006) thus resulting in the activation of the classical complement
cascade only when C1q is plastic immobilized, a situation that mimics C1q bound
to a microbial surface. Anti-inflammatory molecules were shown to modulate
PTX3 expression. Under inflammatory conditions, glucocorticoid hormones
(GCs) induce and enhance the protein expression in fibroblasts but not in myeloid
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cells (Doni et al. 2008). Also HDLs, which possess a series of vascular protective
activities, induce PTX3 expression in endothelial cells (Norata et al. 2008). The
latter mechanism requires the activation of the PI3K/Akt pathway through
G-coupled lysosphingolipid receptors and is mimicked by sphingosine-1-phosphate
and others S1P mimetics (Norata et al. 2008), physiologically present in HDL and
responsible for some of the activities linking HDL to the immunoinflammatory
response (Norata et al. 2005, 2012). In vivo, an increased expression of PTX3
mRNA was detected in the aorta of transgenic mice overexpressing human apoA-I,
compared to apoA-I knockout mice, and plasma levels of PTX3 are significantly
increased in C57BL/6 mice injected with HDL (Norata et al. 2008). These data
suggest that some of the beneficial effects in immunity of HDLmay result also from
the modulation of molecules that act as sensors of the immunoinflammatory
balance.
In summary, all the observations showing that the increase of HDL is associated
with an attenuation of LPS-induced inflammatory response (Levine et al. 1993; van
Leeuwen et al. 2003) strongly favor the hypothesis that raising plasma HDL may
represent a therapeutic approach in the treatment of sepsis and its complications.
The picture however is more complicated, and not only HDL quantity but also HDL
quality/composition is critical. For instance, the increase in sepsis-related mortality
of the ILLUMINATE trial observed in the torcetrapib (a cholesteryl ester transfer
protein inhibitor, increasing HDL-C levels) arm (Barter et al. 2007) was unlikely
due to a direct effect of torcetrapib on LBP or bactericidal/permeability increasing
protein function nor to inhibition of an interaction of CETP with LPS (Clark
et al. 2010). It is rather possible that changes in plasma lipoprotein composition
despite increased HDL levels, or the known off-target effects of torcetrapib, such as
aldosterone elevation, could have aggravated the effects of sepsis (Clark
et al. 2010). Apolipoprotein mimetic peptides represent an emerging area of HDL
therapy; the most effective apoA-I mimetic peptide is 4F, which has been shown to
improve HDL quality/function (Sherman et al. 2010; White et al. 2009). 4F mimics
also anti-inflammatory properties of HDL: in vitro, 4F inhibits the expression of
pro-inflammatory mediators in LPS-treated cells by directly binding to LPS, thus
resulting in the inhibition of LPS binding to LBP (Gupta et al. 2005). In
endotoxemic rats, the administration of 4F after LPS injection results in the
attenuation of acute lung injury and increased survival, probably due to the preser-
vation of circulating HDL-C and the downregulation of inflammatory pathways
(Kwon et al. 2012); 4F also prevents defects in vascular functions and is associated
with a decrease in plasma endotoxin activity in rats (Dai et al. 2010) and improved
cardiac performance in LPS-treated rats (Datta et al. 2011). These observations
indicate that, by scavenging LPS, 4F may prevent LPS-induced release of
pro-inflammatory cytokines and changes in HDL composition resulting in an
effective reduction of clinical complications associated with sepsis. Although
promising, future studies are warranted to translate these findings into the clinical
setting.
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3 HDL and Parasitic Infections
The connection between HDL and parasitic infections mainly relates on the ability
of specific apolipoproteins, which circulate as part of the HDL3 complex, to limit
Trypanosoma brucei or Leishmania infection. The most relevant apolipoprotein in
this context is apoL-1 which was discovered in 1997 (Duchateau et al. 1997) and
was shown to be a part of a primate-specific complex named trypanosome lytic
factor-1 (TLF-1) that also contains apoA-I and haptoglobin-related protein as the
main protein components. TLF-1 has lytic activity toward African Trypanosoma
brucei brucei and renders humans and most other primates resistant to infection
with this parasite causing endemic infections of African cattle. The Trypanosoma
species brucei rhodesiense and brucei gambiense, however, are resistant to TLF-1
and cause sleeping sickness in humans. Sleeping sickness is fatal when untreated
and thus is an important health problem in many African countries. The trypano-
some lytic activity has been associated with apoL-1 (Vanhamme et al. 2003); the
apoL-1-containing complex is taken up by T. b. brucei via a receptor that binds
hemoglobin and haptoglobin-related protein (Hb-Hpr). ApoL-1 traffics to the
trypanosomal lysosome, where the acidic pH causes a conformational change,
leading to activation of anion channel function in the apoL-1 N terminus. Lyso-
somal swelling kills the trypanosome (Perez-Morga et al. 2005). Thus, apoL-1
confers innate immunity against this parasite (Wheeler 2010). Over time, T. b.
brucei developed a virulence factor called SRA that can inactivate apoL-1 protein,
although the cellular location of this interaction is unknown. These SRA-expressing
trypanosomes evolved into T. b. rhodesiense, the etiologic agent that causes acute
African sleeping sickness (Wheeler 2010). This discovery has now been used to
engineer a potential fusion protein drug for treating sleeping sickness caused by
brucei rhodesiense in human (Baral et al. 2006). The active component in the novel
protein drug candidate is a recombinant apoL-1 where the C-terminal SRA-binding
region of wild-type apoL-1 has been deleted. This truncated apoL-1 alone probably
has low biological activity when injected into plasma due to competition with
endogenous apoL-1 (~6 mg/l) for uptake by trypanosomes. To circumvent this
problem and effectively target recombinant apoL-1 to trypanosomes, the
SRA-resistant apoL-1 without the C-terminal sequences was fused with a fragment
of a high-affinity camel antibody (designated nanobody) specifically recognizing
conserved epitopes of variant surface glycoprotein on trypanosomes (Baral
et al. 2006). In vitro, the recombinant apoL-1–nanobody specifically bound to
trypanosomes and was capable of lysing them in vivo. When mice infected with
Trypanosoma brucei brucei were treated with the apoL-1–nanobody fusion protein,
the parasites were promptly cleared from the circulation.
Another trypanosomatida, Leishmania, is also targeted by apoL-1 (Samanovic
et al. 2009). It is certainly possible that apoL-1 has broad innate immunity
properties, shaping the relative frequencies of the APOL1 alleles. Of note the
chronic kidney disease (CKD)-associated G1 and G2 variants (Parsa et al. 2013)
encode forms of apoL-1 that evade SRA and remain active against T. b.
rhodesiense. This, and/or other biological effects, may have conferred a selective
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advantage to G1 and G2 heterozygotes, causing a selective sweep. The contribution
of apoL-1 to CKD could also be related to the HDL functionality (Baragetti
et al. 2013) under specific immunopathological conditions such as those observed
during CKD. Hence, HDL could represent the bridge between apoL-1 and CKD and
should be taken into consideration when exploring the contribution of apoL-1 to the
disease. The delineation of how primates in late evolution have exploited HDL to
fight parasite infections highlights the need of investigations on other potential roles
of plasma HDL beyond those in lipid metabolism and reverse cholesterol transport.
4 HDL and Viral Infections
Changes in plasma HDL-C levels have been reported to occur also during infection
with viruses including human immunodeficiency virus (HIV) and hepatitis C virus
(HCV). Furthermore, proteins related to HDL life cycle, such as SR-BI, were shown
to play a key role in HCV infection. So far HDLs were proposed to increase virus
infection and inhibit virus neutralizing antibodies; however, recent findings are
challenging previous data and proposing a more complicated picture based on the
ability of virus to take advantage of HDL–lipid transfer activity in host cells. Most
of the available evidences linking HDL to viral infection are available for HIV
and HCV.
4.1 HIV Infection
HIV infects and depletes CD4 lymphocytes, resulting in immunodeficiency and a
slowly progressive disease. HIV is associated with dyslipidemia, namely,
hypocholesterolemia, low levels of LDL, and hypertriglyceridemia (Riddler
et al. 2003; Shor-Posner et al. 1993). HIV infection is commonly associated also
with hypoalphalipoproteinemia; however, it is unclear whether virion replication
plays a causative role in these changes. Some data suggest that hypoalphalipopro-
teinemia in patients with HIV is likely to be secondary to HIV infection itself (Rose
et al. 2006). Systemic inflammation has been shown to lower the antioxidant and
anti-inflammatory activity by transforming HDL to a pro-oxidant,
pro-inflammatory acute-phase HDL (Kelesidis et al. 2013; Norata et al. 2006). A
small pilot study of HIV-1-infected individuals with suppressed viremia on combi-
nation antiretroviral therapy showed that oxidative stress and inflammation in
HIV-1 are associated with a marked reduction of HDL antioxidant–anti-inflamma-
tory activities. In vitro, these abnormalities were significantly improved by treat-
ment with the apoA-1 mimetic peptide 4F (Kelesidis et al. 2011). HIV infection is
associated with modified HDL metabolism redirecting cholesterol to the apoB-
containing lipoproteins and likely reducing the functionality of reverse cholesterol
transport (Rose et al. 2008). Of note, the HIV-1 Nef protein can impair ABCA1
cholesterol efflux from macrophages, thus supporting atherosclerosis. This viral
inhibition of efflux was correlated with a direct interaction between ABCA1 and
Nef (Fitzgerald et al. 2010; Mujawar et al. 2006). More recently it was shown that
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Nef downregulates ABCA1 function by a posttranslational mechanism that
stimulates ABCA1 degradation but does not require the ability of Nef to bind
ABCA1 (Mujawar et al. 2010).
Not all data are however concordant on this, and although HDL cholesterol and
preβ1-HDL were significantly lower in all HIV-infected groups ( p< 0.05), mean
levels of apoA-I and the ability of plasma to promote cholesterol efflux were similar
in treatment-naı¨ve HIV-infected patients or in HIV-infected patients on long
therapy break. Of note a positive correlation between apoA-I and levels of CD4+
cells was also observed (r2¼ 0.3, p< 0.001) (Rose et al. 2008). Furthermore apoA-
I, the major protein component of high-density lipoprotein, and its amphipathic
peptide analogue were found to inhibit cell fusion, both in HIV-1-infected T cells
and in recombinant vaccinia-virus-infected CD4+ HeLa cells expressing HIV
envelope protein on their surfaces (Srinivas et al. 1990). The amphipathic peptides
inhibited the infectivity of HIV-1. The inhibitory effects were manifest when the
virus, but not cells, was pretreated with the peptides. Also, a reduction in
HIV-induced cell killing was observed when virus-infected cell cultures were
maintained in the presence of amphipathic peptides. These results have potential
implications for HIV biology and therapy (Srinivas et al. 1990).
An aspect debated is how much the HIV infection and/or treatment contribute to
the changes in HDL-C levels. With highly active antiretroviral therapy (HAART)
intervention, mortality due to HIV was greatly reduced (Madamanchi et al. 2002).
However, there have been several reports of increases in cardiovascular
complications in patients with HIV. It is now established that some HAART
regimens cause severe dyslipidemia, characterized by high levels of TC and
LDL-C, hypertriglyceridemia, and hypoalphalipoproteinemia (Riddler
et al. 2003). This clearly pro-atherogenic lipoprotein profile is associated with a
rise in the incidence of CAD (Depairon et al. 2001). The rate of inflammation
predicts changes in HDL-C and apoA-I following the initiation of antiretroviral
therapy and indeed in a subgroup of participants not taking ART at study entry who
were randomized in the Strategies for Management of Antiretroviral Therapy
(SMART) to immediately initiate ART (“VS group”) or to defer it (“DC group”);
HDL-C and ApoA-I levels increased among VS participants (n¼ 128) after starting
ART compared to DC. The effect of starting ART on changes in HDL-C and apoA-I
was greater for those with higher versus lower baseline levels of IL-6 or hsCRP
indicating that the activation of inflammatory pathways could contribute to
HIV-associated changes in HDL (Baker et al. 2011). Also non-nucleoside reverse
transcriptase inhibitors (NNRTI), such as nevirapine (NVP), were shown to
increase apoA-I production, which contributes to the HDL-C increase after intro-
duction of NVP-containing regimens. In view of the potent anti-atherogenic effects
of apoA-I, the observed increase was suggested to contribute to the favorable
cardiovascular profile of NVP (Franssen et al. 2009). Also efavirenz, another
NNRTI antiretroviral treatment, was associated with HDL particles with a better
antioxidant function, i.e., with a higher PON-1 activity. The PON-1 activity of
black patients is higher than that found in whites regardless of treatment suggesting
that ethnicity should be taken into consideration when studying drug effects on
PON-1 activity (Pereira et al. 2009).
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Overall the available evidences suggest that HIV infection could be associated
with modified HDL metabolism redirecting cholesterol to the apoB-containing
lipoproteins and likely reducing the functionality of reverse cholesterol transport
and promote atherosclerosis. Additional pro-atherogenic mechanisms could be
associated with a decrease in the anti-inflammatory properties of HDL.
4.2 HCV Infection
HCV is a major cause of liver cirrhosis and hepatocellular carcinoma. Viral entry is
required for initiation, spread, and maintenance of infection and thus is a promising
target for antiviral therapy. HCV exists in heterogenous forms in human serum and
may be associated with VLDL, LDL, and HDL which can shield the virus from
neutralizing antibodies targeting the HCV envelope glycoproteins (Agnello
et al. 1999; Hijikata et al. 1993; Nielsen et al. 2006; Thomssen et al. 1992). HCV
binding and entry into hepatocytes is a complex process involving the viral enve-
lope glycoproteins E1 and E2, as well as several host factors, including highly
sulfated heparan sulfate, CD81, the low-density lipoprotein receptor, claudin-1,
occludin, and receptor tyrosine kinases (Lupberger et al. 2011; Zeisel et al. 2011).
Also SR-BI which binds a variety of lipoproteins and mediates the selective
uptake of HDL cholesterol ester (CE) as well as bidirectional free cholesterol
transport at the cell membrane emerged as a critical receptor affecting HCV
entry. SR-BI directly binds HCV E2 (Bartosch et al. 2003; Evans et al. 2007;
Scarselli et al. 2002), but virus-associated lipoproteins, including apoB containing,
also contribute to host cell binding and uptake (Dao Thi et al. 2012; Maillard
et al. 2006). Moreover, physiological SR-BI ligands modulate HCV infection
(Bartosch et al. 2005; Voisset et al. 2005; von Hahn et al. 2006), suggesting the
existence of a complex interplay between lipoproteins (not only HDL), SR-BI and
HCV envelope glycoproteins for HCV entry. Earlier studies using small molecule
inhibitors indicated a role for SR-BI lipid transfer function in HCV infection and
HDL-mediated entry enhancement (Bartosch et al. 2003; Dreux et al. 2009; Syder
et al. 2011; Voisset et al. 2005). A human anti-SR-BI mAb has been reported to
inhibit HDL binding, to interfere with cholesterol efflux, and to decrease cell
culture-derived HCV (HCVcc) entry during attachment steps without having a
relevant impact on SR-BI-mediated post-binding steps (Catanese et al. 2007,
2010). However, SR-BI mediates the uptake of HDL-C in a two-step process
including HDL binding and subsequent transfer of CE into the cell without inter-
nalization of HDL; a novel emerging hypothesis suggests that the interference with
SR-BI lipid transfer function may be relevant for both initiation of HCV infection
and viral dissemination independently of HDL function (Zahid et al. 2013).
Indeed SR-BI has also been demonstrated to mediate post-binding events during
HCV entry (Haberstroh et al. 2008; Syder et al. 2011; Zeisel et al. 2007). HCV–SR-
BI interaction during post-binding steps occurs at similar time points as the HCV
utilization of CD81 and claudin-1 suggesting that HCV entry may be mediated
through the formation of co-receptor complexes (Harris et al. 2008; Krieger
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et al. 2010; Zeisel et al. 2007). Also the SR-BI partner PDZK1 was shown to
facilitate hepatitis C virus entry (Eyre et al. 2010).
These data suggest that SR-BI plays a multifunctional role during HCV entry at
both binding and post-binding steps (Catanese et al. 2010). Furthermore the HCV
post-binding function of human SR-BI can be dissociated from its E2-binding
function. Murine SR-BI does not bind E2 although it is capable of promoting
HCV entry (Catanese et al. 2010; Ploss et al. 2009), and SR-BI, although able to
directly bind E2 and virus-associated lipoproteins, could play additional functions
during HCV infection (Bartosch et al. 2003; Dreux et al. 2009; Zeisel et al. 2007).
Although the addition of HDL enhances the efficiency of HCVcc infection, anti-
SR-BI antibodies and SR-BI-specific siRNA efficiently inhibited HCV infection
independently of lipoproteins (Zeisel et al. 2007). In this context, the post-binding
activity of SR-BI is of key relevance for cell-free HCV infection as well as cell-to-
cell transmission and by using antibodies which do not inhibit HDL binding to
SR-BI; it was observed that post-binding function of SR-BI appears to be unrelated
to HDL interaction but to be directly linked to its lipid transfer function (Zahid
et al. 2013). So far small molecules and mAbs targeting SR-BI and interfering with
HCV infection have been described (Bartosch et al. 2003; Catanese et al. 2007;
Syder et al. 2011). A codon-optimized version of this mAb has been demonstrated
to prevent HCV spread in vivo (Meuleman et al. 2012), and ITX5061, a SR-BI
inhibitor, is in clinical development as HCV entry inhibitor (phase I, http://
clinicaltrials.gov/ct2/show/NCT01560468?term¼ITX+5061&rank¼3).
Despite this promising approach, some open questions remain. First, it has been
shown in vitro that apoA-I is required for HCV production (Mancone et al. 2011)
and that serum amyloid A has antiviral activities against HCV which are reduced
when HDL are co-incubated with SAA (Lavie et al. 2006). Given the changes
between apoA-I and SAA occurring in HDL during the acute phase (Norata
et al. 2012), it is still unknown whether this mechanism could be the consequence
of viral infection or may represent part of the immune response which HCV learned
to escape. Second, as the inhibition of SR-BI represents one of the most promising
targets for HCV infection, the potential side effects on the impairment of HDL
function should be carefully evaluated. The new data showing that HCV infection
does not require receptor-E2–HDL interactions, coupled with the observation that
HCV entry and dissemination can be inhibited without blocking HDL–SR-BI
binding (Zahid et al. 2013), open a novel perspective for the design of entry
inhibitors interfering specifically with the proviral function of SR-BI.
Conclusion
HDLs are emerging as a relevant player in both innate and adaptive immunity
(Norata et al. 2011, 2012; Sala et al. 2012). HDL activities rely not only on the
ability to modulate cholesterol availability in immune cells but also on the role
of specific molecules shuttled by HDL. During infections and acute conditions,
HDL-C levels decrease very rapidly, and HDL particles undergo changes that
dramatically alter their composition and function. Whether this is the conse-
quence of a humoral innate response aimed at scavenging lipid bacterial
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products such as LPS from the circulation and driving them into the liver for
catabolism and elimination is still debated. Experimental evidence in genetically
manipulated animal models suggests, however, that alterations in HDL struc-
ture/composition are associated with poor prognosis following endotoxemia or
sepsis, further supporting a protective role for HDL. The same is true for some
parasitic infections, where the key player appears to be a specific and minor
apolipoprotein of HDL–apoL-1. For viral infections, the landscape is more
complicated; SR-BI was clearly indicated as a player favoring virus entry;
however, it is not clear whether viruses, such as HCV, evolved to take advantage
of the HDL–SR-BI interaction to entry liver cells as in vitro studies suggest or
whether in vivo HDL can compete for the interaction between HCV and SR-BI.
Further studies are warranted in this context. Despite this, proteins related to
HDL physiology represent already a target in clinical development for
infections, and SR-BI antagonism represents a novel and forefront approach to
interfere with hepatitis C virus entry.
All the observations showing that the increase of HDL-C is associated with an
attenuation of LPS-induced inflammatory responses strongly favor the hypothe-
sis that raising plasma HDL may represent a therapeutic approach in the treat-
ment of sepsis and its complications (Table 1). HDL-related therapies are of
great interest also in the context of parasites and virus infections (Table 1). As of
beginning of 2014, the research in the field of HDL and immunity is in its
infancy compared to the body of data available for HDL and atherosclerosis.
From the coming years, we have to expect new and compelling observations
further linking HDL to innate immunity.
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Table 1 HDL-related therapies and infections
Compound References
Endotoxemia/
LPS scavenging
Recombinant
HDL
Parker et al. (1995),
Pajkrt et al. (1996)
ApoA-I
mimetics
Gupta et al. (2005)
Parasites
infections
Trypanosoma
Leishmania
ApoL-1–
nanobody
Baral et al. (2006),
Samanovic et al. (2009)
Hepatitis C virus
entry
SR-BI
monoclonal
antibodies
Bartosch et al. (2003), Catanese et al. (2007),
Meuleman et al. (2012), Syder et al. (2011)
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